MedTrace Logo

Harmonized AS/MQ Efficacy Study - Thailand

NCT02052323 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-01-25

No results posted yet for this study

Summary

The purposes of this study is to determine parasitological clearance rates by microscopy for the 72-hour period after first artesunate dose in subjects with uncomplicated P. falciparum malaria.

Conditions

Interventions

DRUG

Artesunate/mefloquine (AS/MQ)

* artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours * mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours * primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours

Sponsors & Collaborators

  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED

  • Global Emerging Infections Surveillance and Response System

    collaborator FED

  • Armed Forces Research Institute of Medical Sciences, Thailand

    lead OTHER_GOV

Principal Investigators

  • Krisada Jongsakul, MD · Armed Forces Research Institute of Medical Sciences, Thailand

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052323 on ClinicalTrials.gov